Saturday, November 21, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

ResMed’s Profitability Metrics Under Scrutiny Following Strong Quarterly Results

Jackson Burston by Jackson Burston
February 19, 2026
in Analysis, Earnings, Healthcare
0
Resmed Stock
0
SHARES
63
VIEWS
Share on FacebookShare on Twitter

Shares of ResMed are consolidating near the $258 mark, taking a pause after a robust second fiscal quarter performance. The company’s recent figures, highlighted by an 11% revenue increase, have shifted investor attention toward the sustainability of this growth trajectory. The central question for the remainder of fiscal 2026 is whether the medical device firm can maintain its current levels of profitability.

Operational Efficiency and Margin Sustainability

A key metric for market observers in the coming months will be the gross margin trend. The last quarter saw this figure reach 62.3% on a non-GAAP basis, driven primarily by lower freight expenses and more efficient manufacturing processes. The focus now is on ResMed’s ability to sustain this performance within the management-guided range of 62% to 63%, amid concerns that rising operational costs could apply pressure.

An Unexpected Catalyst from GLP-1 Medications

Contrary to initial market apprehensions, weight-loss drugs known as GLP-1 agonists have not materialized as a threat to the core sleep apnea therapy business. Recent company data indicates a positive correlation: patients prescribed GLP-1 medications are 10% to 11% more likely to initiate positive airway pressure (PAP) therapy. This trend suggests the drugs could become a structural tailwind, potentially boosting long-term demand for CPAP devices.

Should investors sell immediately? Or is it worth buying Resmed?

Shareholder Returns and Forward Strategy

The company has confirmed a quarterly dividend of $0.60 per share, payable on March 19, 2026. Concurrently, management continues its capital return initiative, with share repurchases exceeding $600 million planned for the full 2026 fiscal year. This substantial buyback program is expected to provide ongoing support for earnings per share (EPS).

Looking ahead, ResMed is scheduled to release its third-quarter results around late April. In the interim, strategic emphasis is being placed on the rollout of digital health platforms. Features powered by artificial intelligence, such as the “Comfort Match” algorithm, are central to this effort, aiming to enhance patient adherence and secure recurring revenue from the consumables and accessories segment.

Ad

Resmed Stock: Buy or Sell?! New Resmed Analysis from November 21 delivers the answer:

The latest Resmed figures speak for themselves: Urgent action needed for Resmed investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 21.

Resmed: Buy or sell? Read more here...

Tags: Resmed
Jackson Burston

Jackson Burston

Related Posts

SAP Stock
Analysis

SAP’s Buyback Machine Grinds On, But the Analyst Chorus Is Turning Sour

September 7, 2026
Münchener Rück Stock
Analysis

Munich Re’s Monte Carlo Warning Collides With Wall Street’s Widest Analyst Split in Years

September 7, 2026
Nvidia Stock
AI & Quantum Computing

Nvidia’s Insider Sales and $12.9 Billion Acquisition Paint a Portrait of a Company in Overdrive

September 7, 2026
Next Post
XRP Stock

XRP Market Dynamics: A Tale of Whale Movements and Contradictory Data

PennantPark Floating Rate Capital Stock

PennantPark Floating Rate Capital: A Critical Support Level Test

Corsair Gaming Stock

Corsair Gaming Pivots Strategy Amid Market Pressures

Recommended

WM stock news

Spire Wealth Management Shows Confidence in Churchill Downs Incorporated with New Acquisition and Bet on Future Growth

3 years ago
Chevron Stock

Chevron Shares Surge Amid Global Oil Supply Disruption

8 months ago
Q2 Holdings Stock

Inclusion in S&P SmallCap 600 Index Ignites Q2 Holdings Stock Rally

1 year ago
REV Stock

REV Group Shares Hit Record High Amid Political Scrutiny

1 year ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum DroneShield Eli Lilly FALLBACK Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Netflix Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power Robinhood Rocket Lab USA Salesforce Strategy Take-Two Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics XRP
No Result
View All Result

Highlights

Nvidia Posts a Record Quarter, but Rate-Hike Fears Still Set the Tone

Home Depot Beats, Shares Slip: Bigger Tickets, Fewer Customers

Rotation, Not Panic: Retailers Test Where Tech’s Money Went

At 5.15%, the 10-Year Treasury Picks the Winners

Bitcoin Slips Below $70,000, and a Samsung Rumor Lifts Modine

Huang Exits, Cisco Reports: Who Actually Gets Paid for AI

Trending

CrowdStrike Stock
Newsletter

93% of Stocks Fall as CrowdStrike Courts Zscaler

by Stephanie Dugan
November 21, 2026
0

Dear readers, The question heading into Friday was whether Anthropic would hold its $83 offer price. It...

Nvidia Stock

Anthropic Lists at a Premium, but the Sell-Off Keeps Going

November 20, 2026
Bitcoin Stock

Anthropic’s $81 Billion IPO Meets a Market in Need of Good News

November 19, 2026
Nvidia Stock

Nvidia Posts a Record Quarter, but Rate-Hike Fears Still Set the Tone

November 18, 2026
Home Depot Stock

Home Depot Beats, Shares Slip: Bigger Tickets, Fewer Customers

November 17, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • 93% of Stocks Fall as CrowdStrike Courts Zscaler
  • Anthropic Lists at a Premium, but the Sell-Off Keeps Going
  • Anthropic’s $81 Billion IPO Meets a Market in Need of Good News

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com